New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:33 EDTCVMCEL-SCI reports continued increase in patient enrollment in Phase III trial
CEL-SCI Corporation announced that during the month of May the company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine. A total of 49 patients were enrolled over the past three months, with 14 patients enrolled in March, 21 in April, and 14 in May of 2014. This marks a continued increase over the prior three month period when a total of 18 patients had been enrolled, with 4 enrolled in December 2013, 8 in January, and 6 in February 2014. So far, a total of 197 patients have been enrolled in the study. The study is expected to complete enrollment of 880 patients by the end of 2015.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
18:51 EDTCVMOn The Fly: After Hours Movers
Subscribe for More Information
16:57 EDTCVMCEL-SCI down 17.7% after announcing proposed offering of common stock, warrants
16:31 EDTCVMCEL-SCI announces proposed offering of common stock, warrants, no amount given
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use